
Sign up to save your podcasts
Or


Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care.
Listen to the podcast to hear Dr. Kaklamani explain:
By Breastcancer.org4.3
4242 ratings
Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care.
Listen to the podcast to hear Dr. Kaklamani explain:

21,941 Listeners

1,115 Listeners

2,033 Listeners

1,691 Listeners

2,637 Listeners

3,493 Listeners

9,295 Listeners

53 Listeners

4,489 Listeners

328 Listeners

388 Listeners

20,212 Listeners

1,177 Listeners

120 Listeners

30 Listeners